Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) EBITDA Margin (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed EBITDA Margin for 6 consecutive years, with 12241.26% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin fell 1279411.0% year-over-year to 12241.26%, compared with a TTM value of 12072.31% through Sep 2025, down 91558.0%, and an annual FY2024 reading of 425.76%, up 746651.0% over the prior year.
  • EBITDA Margin was 12241.26% for Q3 2025 at Barinthus Biotherapeutics, up from 1282900.0% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1666800.0% in Q4 2021 and bottomed at 1282900.0% in Q2 2025.
  • Average EBITDA Margin over 5 years is 31543.01%, with a median of 2569.62% recorded in 2022.
  • The sharpest move saw EBITDA Margin crashed -166718862bps in 2022, then surged 13614576bps in 2023.
  • Year by year, EBITDA Margin stood at 1666800.0% in 2021, then crashed by -100bps to 388.62% in 2022, then soared by 35033bps to 135757.14% in 2023, then crashed by -113bps to 17994.77% in 2024, then skyrocketed by 32bps to 12241.26% in 2025.
  • Business Quant data shows EBITDA Margin for BRNS at 12241.26% in Q3 2025, 1282900.0% in Q2 2025, and 4750.63% in Q1 2025.